SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Cannabis > Zynerba Pharmaceuticals (ZYNE)

ANALYST UPGRADES ZYNERBA, ENCOURAGED BY PROSPECTS FOR FRAGILE

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
cjstocksup Member Profile
Member Level 
Followed By 2,898
Posts 209,187
Boards Moderated 2
Alias Born 07/30/07
160x600 placeholder
Dangerous Opioid Side Effects Shift Market Focus to Cannabis for Chronic Pain "NetworkNewsWire" - 12/13/2017 8:45:00 AM
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management "NetworkNewsWire" - 12/6/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 12/4/2017 7:31:33 AM
Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 ... "GlobeNewswire Inc." - 12/3/2017 12:01:00 PM
Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES) "GlobeNewswire Inc." - 11/21/2017 9:00:00 AM
Innovation Drives Value for Leading Cannabis Biotechs "NetworkNewsWire" - 11/15/2017 8:45:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/14/2017 8:03:15 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/14/2017 7:31:54 AM
Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights "GlobeNewswire Inc." - 11/14/2017 7:30:00 AM
Biotech M&A Momentum Attractive for Cannabinoid R&D Space "NetworkNewsWire" - 11/7/2017 8:45:00 AM
Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences "GlobeNewswire Inc." - 11/7/2017 7:30:00 AM
Economic Impact of Biosynthesis on the Cannabis Industry "NetworkNewsWire" - 10/31/2017 8:45:00 AM
Innovative Biotechnology Companies are Transforming Cannabis-based Medical Products "NetworkNewsWire" - 10/26/2017 8:45:00 AM
How Biosynthesis is Revolutionizing Cannabinoid Pharmaceuticals "NetworkNewsWire" - 10/24/2017 8:45:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/23/2017 7:26:26 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 10/11/2017 8:01:50 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:09:06 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:08:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 10/3/2017 4:07:22 PM
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development "NetworkNewsWire" - 9/28/2017 8:45:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/28/2017 7:02:33 AM
Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile... "GlobeNewswire Inc." - 9/28/2017 6:30:00 AM
Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development "NetworkNewsWire" - 9/26/2017 8:45:00 AM
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects "NetworkNewsWire" - 9/19/2017 8:45:00 AM
Biosynthesis Technology Could Transform Cannabinoid Production "NetworkNewsWire" - 9/13/2017 8:45:00 AM
cjstocksup Member Level  Tuesday, 10/03/17 12:46:58 AM
Re: stocky101 post# 899
Post # of 1013 
ANALYST UPGRADES ZYNERBA, ENCOURAGED BY PROSPECTS FOR FRAGILE X PHASE 2 STUDY

1:42PM ET 10/2/17


Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) investors may have reason for cautious optimism after the company's recent Fragile X Syndrome treatment data. On Monday, Cantor Fitzgerald analyst Elemer Piros upgraded Zynerba to Overweight and said there is a reasonable change ZYN002 will find commercial success as a treatment for Fragile X. According to Piros, Cantor Fitzgerald sees a 30 percent probability of ZYN002 making it to the Fragile X market (see his track record here). However, even with less than a one in three chance of success, the Fragile X data has created some major value potential in Zynerba stock. Related Link: Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain "Based on the positive Phase 2 FXS results, we are encouraged by the potential for ZYN002 to treat the disease and have assessed the risk-adjusted opportunity for the drug," Elemer said. "With an annual price assumption of $45,000 (U.S.) and $32,000 (EU), ZYN002 could reach combined peak sales of $1.5 billion, in our calculation." For now, the firm is waiting for additional data and information from the company related to potential fundraising. Elemer expects Zynerba will secure additional financing within the next one to two years and will begin a phase II/III study in early 2018. Cantor Fitzgerald estimates Zynerba will finish 2018 with roughly $73 million in cash on its balance sheet. Elemer said ZYN002's potential Fragile X indication adds roughly $13 per share of risk-adjusted value to Zyberba. Cantor Fitzgerald has raised its price target for the stock accordingly, from $4 to $17. Zynerba's stock initially jumped 52 percent last week on the news but remain down more than 40 percent year to date. At time of publication, shares of Zynerba were up 3.91 percent at $8.69.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist